All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the ways in which antibodies work. When IgG antibodies interact with target cells (virus-infected cells and tumor cells) through the Fab fragment, the surface epitopes After specific binding, its Fc segment can bind with FcγR killer cells (NK cells, monocytes-macrophages, neutrophils) and other effector cells, trigger the killing activity of effector cells, and directly kill target cells (virus infection Cells and tumor cells).
ADCC action is an ideal mechanism for antibody drugs to kill target cells, and the anti-tumor activity of monoclonal antibodies can be verified through ADCC test. Early ADCC verification methods are mostly based on freshly prepared peripheral blood mononuclear cells or NK cells as effector cells. However, these methods have disadvantages such as difficulty in cell classification and culture, cumbersome operation, high background value, and being affected by individual differences. .
In order to solve the common problems in the traditional ADCC test, Ceative Biolabs uses the luciferase reporter gene detection system as a platform to construct Jurkat-NFAT-Luc stably transfected with CD16 receptor and NFAT (Nuclear Factor of Activated T-cells) reaction element -CD16 cell line. When the Fab segment of the antibody binds to the antigen on the target cell, the Fc segment of the antibody binds to the (FcγRIIIA) on the surface of the effector cell Jurkat-NFAT-Luciferase-CD16 cell, causing the activation of the NFAT-related signaling pathway in the cell, which in turn induces the expression of luciferase.
There are currently no customer reviews or questions for Human Peripheral Blood Leukemia T Stable Cell Line Jurkat, NFAT/Luciferase/CD16 Overexpressed (CAR-STC-ZP4). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION